Evidence map›Paper›PMID 29845931›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2018

Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015.

Kamilla Laut, Leah Shepherd, Roxana Radoi, Igor Karpov, Milosz Parczewski, Cristina Mussini, Fernando Maltez, Marcelo Losso, Nikoloz Chkhartishvili, Hila Elinav and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Kamilla LautCHIP, Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Leah ShepherdCentre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom.
Roxana RadoiSpitalul Clinic de Boli Infectioase si Tropical, "Dr. Victor Babes", Bucharest, Romania.
Igor KarpovDepartment of Infectious Diseases, Belarus State Medical University, Minsk, Belarus.
Milosz ParczewskiDepartment of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Szczecin, Szczecin, Poland.
Cristina MussiniClinica delle Malattie Infettive e Tropicali, Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
Fernando MaltezHospital de Curry Cabral, Serviço de Doenças Infecciosas, Lisbon, Portugal.
Marcelo LossoCoordinación de Investigación Clinica Académica en Latinoamérica, Buenos Aires, Argentina.
Nikoloz ChkhartishviliInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.
Hila ElinavDepartment of Clinical Microbiology and Infectious Diseases, Hadassah Hospital, Jerusalem, Israel.
Helen KovariDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Anders BlaxhultDepartment of Infectious Diseases, Venhälsan, Södersjukhuset, Stockholm, Sweden.
Robert ZangerleMedical University of Innsbruck, Department of Dermatology, Venereology and Allergology, Innsbruck, Austria.
Tatiana TrofimovaNovgorod Centre for AIDS Prevention and Control, Velikij Novgorod, Russia.
Malgorzata InglotMedical University Wroclaw, Wroclaw, Poland.
Kai ZilmerCentre of Infectious Diseases, West-Tallin Central Hospital, Tallin, Estonia.
Elena KuzovatovaNizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina, Nizhny Novgorod, Russia.
Thérèse StaubCentre Hospitalier de Luxembourg, Service des Maladies Infectieuses, Luxembourg.
Dorthe RabenCHIP, Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Jens LundgrenCHIP, Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Amanda MocroftCentre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom.
Ole KirkCHIP, Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
EuroSIDA Study GroupThe members of the EuroSIDA Study Group are acknowledged at the end of the article.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDirect comparisons between countries in core HIV care parameters are often hampered by differences in data collection.

aimWithin the EuroSIDA study, we compared levels of antiretroviral treatment (ART) coverage and virological suppression (HIV RNA < 500 copies/mL) across Europe and explored temporal trends.

methodsIn three cross-sectional analyses in 2004-05, 2009-10 and 2014-15, we assessed country-specific percentages of ART coverage and virological suppression among those on ART. Temporal changes were analysed using logistic regression.

resultsOverall, the percentage of people on ART increased from 2004-05 (67.8%) to 2014-15 (78.2%), as did the percentage among those on ART who were virologically suppressed (75.2% in 2004-05, 87.7% in 2014-15). However, the rate of improvement over time varied significantly between regions (p < 0.01). In 2014-15, six of 34 countries had both ART coverage and virological suppression of above 90% among those on ART. The pattern varied substantially across clinics within countries, with ART coverage ranging from 61.9% to 97.0% and virological suppression from 32.2% to 100%. Compared with Western Europe (as defined in this study), patients in other regions were less likely to be virologically suppressed in 2014-15, with the lowest odds of suppression (adjusted odds ratio = 0.16; 95% confidence interval (CI): 0.13-0.21) in Eastern Europe.

conclusionsDespite overall improvements over a decade, we found persistent disparities in country-specific estimates of ART coverage and virological suppression. Underlying reasons for this variation warrant further analysis to identify a best practice and benchmark HIV care across EuroSIDA.

Indexed as

Sustained Virologic ResponseAdultAnti-Retroviral AgentsCD4 Lymphocyte CountCohort StudiesEuropeFemaleHealthcare DisparitiesHIV InfectionsHumansMaleMiddle AgedRNA, ViralTreatment FailureViral LoadAnti-Retroviral AgentsRNA, ViralContinuity of patient careEpidemiologyEuropeHIV infectionSurveillanceTreatment outcome

Identifiers

PMID29845931
PMCPMC6152212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.